Brainstorm Diagnostics
Brainstorm Diagnostics offers the world’s first blood test to diagnose damaged axons in concussion and traumatic brain injury, providing an objective alternative to subjective symptom reporting. The test also predicts which patients will experience delayed recovery, enabling clinicians to stratify risk and tailor follow-up care. It uses a standard blood draw, making it suitable for emergency departments, urgent care, and primary care settings.
- Healthcare Technology
- Biotechnology
- Medical Devices
- Hardware
Funding
Founders
Founder details are not available yet.
Product
Problem
Current concussion and traumatic brain injury diagnosis relies heavily on subjective symptom reporting and clinical examinations, which can miss subtle but significant axonal damage. This often leads to under-diagnosis, delayed treatment, and uncertainty about which patients will experience prolonged recovery, leaving many individuals without appropriate follow-up care.
Solution
Brainstorm Diagnostics has developed a novel blood test that detects biomarkers of axonal damage, providing an objective and quantifiable measure of brain injury. This test not only confirms a concussion diagnosis but also stratifies patients based on their risk for delayed recovery, enabling clinicians to make more informed treatment and monitoring decisions. By offering a simple blood draw, the test makes advanced neurological assessment more accessible and can be integrated into routine emergency and primary care workflows. The predictive capability of the test allows for proactive management of at-risk patients, potentially reducing long-term complications.
Target Audience
Primary customers are emergency departments, urgent care centers, primary care physicians, sports medicine clinics, and neurologists who assess and manage patients with suspected concussion or traumatic brain injury.
Features
- Blood-based biomarker assay specifically targeting axonal proteins released after brain injury
- Predictive algorithm that stratifies patients by risk of delayed recovery or persistent post-concussion symptoms
- Objective diagnostic output that reduces reliance on subjective patient self-reporting
- Standard blood draw process, enabling use in emergency departments, clinics, and urgent care settings
- Results designed to be available within a clinically actionable timeframe to support rapid decision-making